Dapagliflozin Mechanism, Therapeutic Role, and Clinical Applications in Diabetes, Heart Failure, and Kidney Disease

Innovative Research Journals

Dapagliflozin Mechanism, Therapeutic Role, and Clinical Applications in Diabetes, Heart Failure, and Kidney Disease Introduction Dapagliflozin is an oral medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, developed initially for the treatment of type 2 diabetes mellitus (T2DM). Its benefits, however, […]

Read More

 Empagliflozin Mechanism, Clinical Applications, and Therapeutic Impact in Diabetes and Cardiovascular Disease

Innovative Research Journals

 Empagliflozin Mechanism, Clinical Applications, and Therapeutic Impact in Diabetes and Cardiovascular Disease Introduction Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor widely used in the management of type 2 diabetes mellitus (T2DM) and associated cardiovascular and renal comorbidities. Marketed under the brand […]

Read More

Understanding Reduced Ejection Fraction Pathophysiology, Diagnosis, and Management

Innovative Research Journals

Understanding Reduced Ejection Fraction Pathophysiology, Diagnosis, and Management Introduction Reduced ejection fraction (REF), commonly referred to as heart failure with reduced ejection fraction (HFrEF), is a serious and progressive condition in which the heart muscle cannot pump blood effectively. This impairment leads […]

Read More